ALS altered lipid signalling in fast-twitch muscles before neurological symptoms in female mice
Original source
Early and Divergent Lipid Mediator Remodelling in Fast Versus Slow Skeletal Muscles of Female hSOD1G93A Mice. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human, Mouse
A study found early, muscle-specific changes in endocannabinoid and other lipid signalling in female mice modelling amyotrophic lateral sclerosis (ALS). Changes were larger in the fast-twitch tibialis anterior muscle, which underwent severe atrophy, than in the relatively preserved soleus muscle. Blocking the fatty acid amide hydrolase enzyme did not improve weight loss, movement or survival in the mice.
Why this matters
The findings suggest that muscle lipid signalling may be involved in ALS muscle pathology and could be explored as an early treatment target. However, this was preclinical research and does not change treatment for people with ALS. The tested enzyme inhibitor did not improve outcomes in the mouse model.
Limitations and context
The main experiments used female hSOD1G93A mice, with 7–11 animals per group. The human evidence came from muscle transcriptome samples from five people with ALS per group, rather than a treatment study. The findings establish altered signalling, not that these changes cause muscle loss or that targeting them benefits people. The source is a primary research article, and the reported findings require confirmation in larger human studies and clinical trials.